Trial Profile
PDL-1 Inhibition With Avelumab and Concurrent Second-generation ADT in African Americans With Castrate-resistant Metastatic Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2019
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Abiraterone; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 25 Jan 2019 Status changed from not yet recruiting to recruiting.
- 18 Dec 2018 New trial record